title: Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.
abstract: Angiogenesis is the formation of new blood vessels from pre-existing vessels to form capillary networks, which, among other diseases, such as diabetic retinopathy and macular degeneration, is particularly important for tumor growth and metastasis. Thus, depriving a tumor of its vascular supply by means of anti-angiogenic agents has been of great interest since its proposal in the 1970s. This review looks at the common angiogenic inhibitors (angiostatin, endostatin, maspin, pigment epithelium-derived factor, bevacizumab and other monoclonal antibodies, and zoledronic acid) and their current status in clinical trials.
authors: Department of Orthopaedics, University of Melbourne, St. Vincent's Health, P.O. Box 2900, Fitzroy, 3065, Melbourne, Australia. crispin.dass@svhm.org.au
authors: C R
authors: CR
authors: Dass
authors: T M N
authors: TM
authors: Tran
authors: P F M
authors: PF
authors: Choong
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D043168:Angiostatins / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use; D043169:Endostatins / Q000494:pharmacology / Q000627:therapeutic use; D005136:Eye Proteins / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D009414:Nerve Growth Factors / Q000494:pharmacology / Q000627:therapeutic use; D015843:Serpins / Q000494:pharmacology / Q000627:therapeutic use; D000077211:Zoledronic Acid; D000099174:Pigment Epithelium-Derived Factor
chemical_list: D020533:Angiogenesis Inhibitors; D043168:Angiostatins; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004164:Diphosphonates; D043169:Endostatins; D005136:Eye Proteins; D007093:Imidazoles; D009414:Nerve Growth Factors; D015843:Serpins; D000077211:Zoledronic Acid; D000099174:Pigment Epithelium-Derived Factor; C085344:SERPIN-B5